Vycellix
Vycellix is an immuno-centric discovery life science company focused on development of natural killer (NK) cell-based and allogeneic/off-the-shelf cell therapies. The organization develops a universal cell-engineering platform and tumor-targeted multi-antigen engager strategies, generates preclinical proof-of-concept data, collaborates on manufacturing optimization, and is preparing for first-in-human (Phase I) clinical studies.
Industries
Nr. of Employees
small (1-50)
Vycellix
Patents
Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
US-12533338-B2
View DetailsRNA construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US-12128061-B2
View Details
Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
US-12533338-B2
View DetailsRNA construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US-12128061-B2
View DetailsProducts
Multi-antigen engager product candidate for solid tumors
A tumor-specific multi-antigen engager program designed to target solid tumors while addressing toxicity, resistance, and dosing frequency.
Allogeneic cell therapy candidate powered by a universal cell engineering platform
An engineered allogeneic cell therapy candidate developed using a universal cell-engineering platform and CD45-targeted engineering intended to produce immune-privileged, donor-derived therapeutic cells.
VY-M
An ex vivo cell manufacturing reagent which optimizes proliferation of T cells, NK cells and other cells with conserved functional capacity, enabling accelerated large-scale cell expansion.
VY-UC
A single-step CD45 engager allogeneic platform designed to engineer immune-privileged, donor-derived effector cells that eliminate the risk of immune rejection.
VY-OZ
A small molecule ex vivo reagent that enhances gene transduction into cytotoxic lymphocytes and hematopoietic stem cells using viral vectors, and improves gene-editing rates for CRISPR-based systems.
Universal Cells
A highly differentiated universal cell engineering platform (VY-UC) enabling any donor cell to be delivered to any patient without risk of cellular host immune rejection.
Multi-antigen engager product candidate for solid tumors
A tumor-specific multi-antigen engager program designed to target solid tumors while addressing toxicity, resistance, and dosing frequency.
Allogeneic cell therapy candidate powered by a universal cell engineering platform
An engineered allogeneic cell therapy candidate developed using a universal cell-engineering platform and CD45-targeted engineering intended to produce immune-privileged, donor-derived therapeutic cells.
VY-M
An ex vivo cell manufacturing reagent which optimizes proliferation of T cells, NK cells and other cells with conserved functional capacity, enabling accelerated large-scale cell expansion.
VY-UC
A single-step CD45 engager allogeneic platform designed to engineer immune-privileged, donor-derived effector cells that eliminate the risk of immune rejection.
VY-OZ
A small molecule ex vivo reagent that enhances gene transduction into cytotoxic lymphocytes and hematopoietic stem cells using viral vectors, and improves gene-editing rates for CRISPR-based systems.
Universal Cells
A highly differentiated universal cell engineering platform (VY-UC) enabling any donor cell to be delivered to any patient without risk of cellular host immune rejection.
Services
Partnerships to co-develop approaches and technologies aimed at optimizing manufacturing workflows for cell- and gene-based immunotherapeutics.
Partnerships to co-develop approaches and technologies aimed at optimizing manufacturing workflows for cell- and gene-based immunotherapeutics.
Expertise Areas
- Natural killer (NK) cell therapeutics
- Allogeneic / off-the-shelf cell therapy development
- Cell engineering platform development
- Multi-antigen engager design for solid tumors
Key Technologies
- Natural killer (NK) cell therapy
- Allogeneic/off-the-shelf cell therapy
- Multi-antigen engager (bispecific/multi-specific) design
- CD45-targeted cell engineering
News & Updates
Presentation of proof-of-concept data for a multi-antigen engager platform designed to overcome solid tumor defense mechanisms.
Presentation of proof-of-concept data for an allogeneic cell therapy platform employing a single-step CD45-engager strategy to generate immune-privileged cells.
Announcement of a collaboration to develop proprietary approaches for optimized manufacture of cell-based immunotherapeutic products.
Announcement regarding preparation for a first-in-human (Phase I) study of an allogeneic cell therapy powered by a universal cell-engineering platform.
Presentation of proof-of-concept data for a multi-antigen engager platform designed to overcome solid tumor defense mechanisms.
Presentation of proof-of-concept data for an allogeneic cell therapy platform employing a single-step CD45-engager strategy to generate immune-privileged cells.
Announcement of a collaboration to develop proprietary approaches for optimized manufacture of cell-based immunotherapeutic products.
Announcement regarding preparation for a first-in-human (Phase I) study of an allogeneic cell therapy powered by a universal cell-engineering platform.